CN111053852A - Pharmaceutical composition for reducing postpartum inflammation of sow and preparation method thereof - Google Patents

Pharmaceutical composition for reducing postpartum inflammation of sow and preparation method thereof Download PDF

Info

Publication number
CN111053852A
CN111053852A CN201911404120.7A CN201911404120A CN111053852A CN 111053852 A CN111053852 A CN 111053852A CN 201911404120 A CN201911404120 A CN 201911404120A CN 111053852 A CN111053852 A CN 111053852A
Authority
CN
China
Prior art keywords
parts
vitamin
powder
pharmaceutical composition
sows
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201911404120.7A
Other languages
Chinese (zh)
Inventor
廖瑞波
卢文强
卢宇鑫
梁世仁
吴有林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangxi Aoxin Biotechnology Co ltd
Fujian Aonong Biological Technology Group Co Ltd
Original Assignee
Jiangxi Aoxin Biotechnology Co ltd
Fujian Aonong Biological Technology Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangxi Aoxin Biotechnology Co ltd, Fujian Aonong Biological Technology Group Co Ltd filed Critical Jiangxi Aoxin Biotechnology Co ltd
Priority to CN201911404120.7A priority Critical patent/CN111053852A/en
Publication of CN111053852A publication Critical patent/CN111053852A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/346—Platycodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/634—Forsythia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718—Coptis (goldthread)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/744—Gardenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/808—Scrophularia (figwort)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8964—Anemarrhena
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a pharmaceutical composition for reducing postpartum inflammation of sows and a preparation method thereof, wherein the pharmaceutical composition comprises the following components in parts by weight: 7-13 parts of antipyretic and antitoxic powder, 0.8-1.2 parts of compound amoxicillin powder, 4.2-5.7 parts of compound vitamin, 13-17 parts of glucose and 4.2-5.7 parts of astragalus polysaccharide powder; the preparation method comprises mixing the above materials. Compared with the prior art, the glucose contained in the invention can supplement the energy deficiency of the sows at the stage caused by low feed intake; the ingested compound vitamin can improve the anti-stress capability of the sow and reduce the infection risk of the birth canal in the farrowing process; the scourge-clearing toxin-vanquishing powder and the astragalus polysaccharide powder can improve the health state of the reproductive system of the sow, enhance the immunity, combine the inhibition effect of amoxicillin on bacteria, synergize and reduce the occurrence of postpartum inflammation of the sow.

Description

Pharmaceutical composition for reducing postpartum inflammation of sow and preparation method thereof
Technical Field
The invention belongs to the technical field of livestock breeding, and relates to a pharmaceutical composition for reducing postpartum inflammation of sows and a preparation method thereof.
Background
After delivery of the sow, secretion may be generated in the birth canal, the normal secretion is named as lochia, and the lochia phenomenon disappears after 3-5 days of delivery. The resistance of the sow during the parturition period is weak, and the infection rate of the vagina or the uterus of the sow is increased. Especially, the born piglet has a large body size and the sow which is artificially born has a high proportion of postpartum inflammation.
Aiming at the postpartum inflammation of the sow, the postpartum inflammation condition of the sow is often reduced by feeding health care medicines besides a mode of intramuscular injection of anti-inflammatory medicines after delivery, but the proportion is still higher than 5%. The sow still has a large amount of mucus purulent vaginal secretions to be discharged 7 days after delivery even when oestrous mating, so that the mating rate of the sow is reduced, and even the sow is rejected in advance due to infertility. Meanwhile, the lactation yield of the postpartum inflammatory sows is reduced, the maternal antibody level is low, and a series of piglet health problems are caused.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide the pharmaceutical composition for reducing the postpartum inflammation of the sow and the preparation method thereof, which are used for the sow in parturition and just parturition in a parturition house, can improve the immunity of the sow in parturition and postpartum and reduce the postpartum inflammation proportion of the sow.
The purpose of the invention can be realized by the following technical scheme:
a pharmaceutical composition for reducing postpartum inflammation of sows comprises the following components in parts by weight: 7-13 parts of antipyretic and antitoxic powder, 0.8-1.2 parts of compound amoxicillin powder, 4.2-5.7 parts of compound vitamin, 13-17 parts of glucose and 4.2-5.7 parts of astragalus polysaccharide powder. The glucose can supplement the energy deficiency of the sows caused by low feed intake at the stage.
Preferably, the pharmaceutical composition comprises the following components in parts by weight: 8-12 parts of antipyretic and antitoxic powder, 0.9-1.1 parts of compound amoxicillin powder, 4.5-5.5 parts of compound vitamin, 14-16 parts of glucose and 4.5-5.5 parts of astragalus polysaccharide powder.
Further preferably, the pharmaceutical composition comprises the following components in parts by weight: 10 parts of antipyretic and antitoxic powder, 1 part of compound amoxicillin powder, 5 parts of compound vitamin, 15 parts of glucose and 5 parts of astragalus polysaccharide powder.
Further, the scourge-clearing toxin-vanquishing powder comprises the following components in parts by weight: 1.2 parts of gypsum, 0.3 part of radix rehmanniae, 0.6 part of buffalo horn, 0.2 part of coptis, 0.3 part of gardenia, 0.2 part of tree peony bark, 0.25 part of scutellaria, 0.25 part of red peony root, 0.25 part of figwort, 0.3 part of rhizoma anemarrhenae, 0.3 part of weeping forsythia, 0.25 part of platycodon root, 0.15 part of liquorice and 0.25 part of lophatherum gracile.
Furthermore, the compound amoxicillin powder contains 0.5 to 1.5 weight percent of amoxicillin and 0.2 to 0.3 weight percent of clavulanic acid.
Furthermore, each 1kg of the compound vitamin contains the following components: 1500-3000KIU vitamin A and 200-1000KIU vitamin D31000mg vitamin E500-11500 + 2000mg vitamin B2500-600mg vitamin B65-7mg vitamin B127000mg nicotinamide 5000-.
Preferably, every 1kg of the compound vitamin contains the following components: 2000KIU vitamin A, 600KIU vitamin D3700mg vitamin E, 1300mg vitamin K, 2200mg vitamin C, 1800mg vitamin B11800mg vitamin B2550mg of vitamin B66mg of vitamin B126000mg of nicotinamide, 6000mg of pantothenic acid, 370mg of folic acid and 60mg of biotin.
A preparation method of a pharmaceutical composition for reducing postpartum inflammation of a sow comprises the following steps: the antipyretic and antitoxic powder, the compound amoxicillin powder, the compound vitamins, the glucose and the astragalus polysaccharide powder are uniformly mixed to obtain the pharmaceutical composition.
When the pharmaceutical composition is used, the adhesive is added, and the mixture is stirred and mixed until the mixture becomes paste. The mass percentage of the adhesive in the pharmaceutical composition is 40-60%.
Further, the adhesive is a nursing sow feed. The lactating sow feed is conventional lactating sow feed available in the market. The feed for lactating sows is added as an adhesive, so that the medicinal composition can be adhered into a dough, and the sows can conveniently eat the feed directly. In addition, the lactating sow feed can further supplement energy shortage of the sows at the stage due to low feed intake.
When the pharmaceutical composition is actually applied, the adhesive is added, and then the pharmaceutical composition is directly fed to sows, and each sow is fed with 100g of the health-care medicine every day and fed for 7 days continuously.
Compared with the prior art, the glucose contained in the invention can supplement the energy deficiency of the sows at the stage caused by low feed intake; the ingested compound vitamin can improve the anti-stress capability of the sow and reduce the infection risk of the birth canal in the farrowing process; the scourge-clearing toxin-vanquishing powder and the astragalus polysaccharide powder can improve the health state of the reproductive system of the sow, enhance the immunity, combine the inhibition effect of amoxicillin on bacteria, synergize and reduce the occurrence of postpartum inflammation of the sow. .
Detailed Description
The present invention will be described in detail with reference to specific examples. The present embodiment is implemented on the premise of the technical solution of the present invention, and a detailed implementation manner and a specific operation process are given, but the scope of the present invention is not limited to the following embodiments.
Example 1:
a pharmaceutical composition for reducing postpartum inflammation of sows is prepared by the following steps: 1000 g of antipyretic and antitoxic powder, 100g of compound amoxicillin powder, 500g of compound vitamin, 1500 g of glucose and 500g of astragalus polysaccharide powder are mixed, heated with boiled water and stirred evenly. And 3 kg of lactating sow feed is added, stirred and mixed until the feed is pasty, and then the feed is directly fed to the sow.
120 antenatal sows are selected and divided into two treatment groups, each treatment group has 6 repetitions, and each repetition has 10 pigs. The control group is added with compound amoxicillin powder (500 g/ton) in the feed of the sow, and the test group is fed with about 100g of the health care medicine every day. The two groups of sows have health care for 7 days (3 days before delivery to 4 days after delivery), and the compound amoxicillin powder ingested by the sows is about 1.5 g/day.
During the test period, the test animals are placed in 2 delivery rooms with consistent environmental conditions, the feeding management procedure is carried out according to the original operation specifications of the pig farm, and all the test pigs only cancel the operations of anti-inflammatory drugs except the test regulations and uterus flushing. Wiping the postnatal fossa and vulva with a clean towel soaked with iodine tincture before delivery, and wiping the postnatal fossa and vulva again after delivery; the anti-inflammatory drugs (herba Houttuyniae injection, penicillin, streptomycin) are continuously administered 3 days after delivery, and iodine tincture is used for vulva disinfection. And observing the postpartum lochia condition of the sow twice at 8:30 and 14:30 every day, and recording the inflammation state of the sow for 7 days after delivery according to the ear number. After weaning, the 7-day weaning estrus rate and the number of estrus days were observed and recorded. The experimental data were analyzed using ANOVA in SPSS 19.0(2007) and multiple comparisons were performed using DUNCAN's method with a significance level P of 0.05.
The results are shown in table 1 below:
TABLE 1 post partum inflammatory status of sows
Figure BDA0002348164960000031
Figure BDA0002348164960000041
As can be seen from the data in Table 1, compared with the control group, the average inflammation ratio of the sows fed with the pharmaceutical composition after 7 days is remarkably reduced (P is less than 0.05), and the postnatal inflammation ratio of the test group is controlled to be about 3%. Compared with a control group, the pharmaceutical composition can reduce the average estrus days of the sows and can obviously improve the 7-day off-mating rate of the sows (P is less than 0.05).
Example 2:
a pharmaceutical composition for reducing postpartum inflammation of sows comprises the following components in parts by weight: 7 parts of antipyretic and antitoxic powder, 1.2 parts of compound amoxicillin powder, 4.2 parts of compound vitamin, 17 parts of glucose and 4.2 parts of astragalus polysaccharide powder.
The pestilence-clearing toxin-vanquishing powder comprises the following components in parts by weight: 1.2 parts of gypsum, 0.3 part of radix rehmanniae, 0.6 part of buffalo horn, 0.2 part of coptis, 0.3 part of gardenia, 0.2 part of tree peony bark, 0.25 part of scutellaria, 0.25 part of red peony root, 0.25 part of figwort, 0.3 part of rhizoma anemarrhenae, 0.3 part of weeping forsythia, 0.25 part of platycodon root, 0.15 part of liquorice and 0.25 part of lophatherum gracile.
The compound amoxicillin powder contains 0.5 wt% of amoxicillin and 0.3 wt% of clavulanic acid.
Every 1kg of the compound vitamin contains the following components: 1500KIU vitamin A, 1000KIU vitamin D3500mg vitamin E, 1500mg vitamin K, 2000mg vitamin C, 2000mg vitamin B11500mg of vitamin B2600mg vitamin B65mg of vitamin B127000mg nicotinamide, 5000mg pantothenic acid, 400mg folic acid and 50mg biotin.
The preparation method of the pharmaceutical composition comprises the following steps: mixing the antipyretic and antitoxic powder, the compound amoxicillin powder, the compound vitamins, the glucose and the astragalus polysaccharide powder uniformly to obtain the pharmaceutical composition.
The pharmaceutical composition can be used by adding binder, stirring, and mixing to obtain paste. The mass percentage of the adhesive in the pharmaceutical composition is 45%. The binder is a feed for lactating sows. The lactating sow feed is conventional lactating sow feed available in the market. When the pharmaceutical composition is actually applied, the adhesive is added and then the pharmaceutical composition is directly fed to sows, and 100g of the health-care medicine is fed to each sow every day and the sows are fed continuously for 7 days.
Example 3:
a pharmaceutical composition for reducing postpartum inflammation of sows comprises the following components in parts by weight: 13 parts of antipyretic and antitoxic powder, 0.8 part of compound amoxicillin powder, 5.7 parts of compound vitamin, 13 parts of glucose and 5.7 parts of astragalus polysaccharide powder.
The pestilence-clearing toxin-vanquishing powder comprises the following components in parts by weight: 1.2 parts of gypsum, 0.3 part of radix rehmanniae, 0.6 part of buffalo horn, 0.2 part of coptis, 0.3 part of gardenia, 0.2 part of tree peony bark, 0.25 part of scutellaria, 0.25 part of red peony root, 0.25 part of figwort, 0.3 part of rhizoma anemarrhenae, 0.3 part of weeping forsythia, 0.25 part of platycodon root, 0.15 part of liquorice and 0.25 part of lophatherum gracile.
The compound amoxicillin powder contains 1.5 wt% of amoxicillin and 0.2 wt% of clavulanic acid.
Every 1kg of the compound vitamin contains the following components: 3000KIU vitamin A, 200KIU vitamin D31000mg vitamin E, 1200mg vitamin K, 2500mg vitamin C, 1500mg vitamin B12000mg vitamin B2500mg of vitamin B67mg of vitamin B125000mg nicotinamide, 7000mg pantothenic acid, 320mg folic acid and 70mg biotin.
The preparation method of the pharmaceutical composition comprises the following steps: mixing the antipyretic and antitoxic powder, the compound amoxicillin powder, the compound vitamins, the glucose and the astragalus polysaccharide powder uniformly to obtain the pharmaceutical composition.
The pharmaceutical composition can be used by adding binder, stirring, and mixing to obtain paste. The mass percentage of the adhesive in the pharmaceutical composition is 50%. The binder is a feed for lactating sows. The lactating sow feed is conventional lactating sow feed available in the market. When the pharmaceutical composition is actually applied, the adhesive is added, and then the pharmaceutical composition is directly fed to sows, and each sow is fed with 100g of the health-care medicine every day and continuously fed for 7 days.
Example 4:
a pharmaceutical composition for reducing postpartum inflammation of sows comprises the following components in parts by weight: 8 parts of antipyretic and antitoxic powder, 1.1 parts of compound amoxicillin powder, 4.5 parts of compound vitamin, 16 parts of glucose and 4.5 parts of astragalus polysaccharide powder.
The pestilence-clearing toxin-vanquishing powder comprises the following components in parts by weight: 1.2 parts of gypsum, 0.3 part of radix rehmanniae, 0.6 part of buffalo horn, 0.2 part of coptis, 0.3 part of gardenia, 0.2 part of tree peony bark, 0.25 part of scutellaria, 0.25 part of red peony root, 0.25 part of figwort, 0.3 part of rhizoma anemarrhenae, 0.3 part of weeping forsythia, 0.25 part of platycodon root, 0.15 part of liquorice and 0.25 part of lophatherum gracile.
The compound amoxicillin powder contains 1 wt% of amoxicillin and 0.25 wt% of clavulanic acid.
Every 1kg of the compound vitamin contains the following components: 2000KIU vitamin A, 600KIU vitamin D3700mg vitamin E1300mg of vitamin K, 2200mg of vitamin C and 1800mg of vitamin B11800mg vitamin B2550mg of vitamin B66mg of vitamin B126000mg of nicotinamide, 6000mg of pantothenic acid, 370mg of folic acid and 60mg of biotin.
The preparation method of the pharmaceutical composition comprises the following steps: mixing the antipyretic and antitoxic powder, the compound amoxicillin powder, the compound vitamins, the glucose and the astragalus polysaccharide powder uniformly to obtain the pharmaceutical composition.
The pharmaceutical composition can be used by adding binder, stirring, and mixing to obtain paste. The mass percentage of the adhesive in the pharmaceutical composition is 60%. The binder is a feed for lactating sows. The lactating sow feed is conventional lactating sow feed available in the market. When the pharmaceutical composition is actually applied, the adhesive is added and then the pharmaceutical composition is directly fed to sows, and 100g of the health-care medicine is fed to each sow every day and the sows are fed continuously for 7 days.
Example 5:
a pharmaceutical composition for reducing postpartum inflammation of sows comprises the following components in parts by weight: 12 parts of antipyretic and antitoxic powder, 0.9 part of compound amoxicillin powder, 5.5 parts of compound vitamin, 14 parts of glucose and 5.5 parts of astragalus polysaccharide powder.
The pestilence-clearing toxin-vanquishing powder comprises the following components in parts by weight: 1.2 parts of gypsum, 0.3 part of radix rehmanniae, 0.6 part of buffalo horn, 0.2 part of coptis, 0.3 part of gardenia, 0.2 part of tree peony bark, 0.25 part of scutellaria, 0.25 part of red peony root, 0.25 part of figwort, 0.3 part of rhizoma anemarrhenae, 0.3 part of weeping forsythia, 0.25 part of platycodon root, 0.15 part of liquorice and 0.25 part of lophatherum gracile.
Every 1kg of the compound vitamin contains the following components: 3000KIU vitamin A, 200KIU vitamin D3500mg vitamin E, 1500mg vitamin K, 2000mg vitamin C, 1500mg vitamin B11500mg of vitamin B2600mg vitamin B65mg of vitamin B127000mg nicotinamide, 5000mg pantothenic acid, 400mg folic acid and 50mg biotin.
The preparation method of the pharmaceutical composition comprises the following steps: mixing the antipyretic and antitoxic powder, the compound amoxicillin powder, the compound vitamins, the glucose and the astragalus polysaccharide powder uniformly to obtain the pharmaceutical composition.
The pharmaceutical composition can be used by adding binder, stirring, and mixing to obtain paste. The mass percentage of the adhesive in the pharmaceutical composition is 40%. The binder is a feed for lactating sows. The lactating sow feed is conventional lactating sow feed available in the market. When the pharmaceutical composition is actually applied, the adhesive is added and then the pharmaceutical composition is directly fed to sows, and 100g of the health-care medicine is fed to each sow every day and the sows are fed continuously for 7 days.
The embodiments described above are described to facilitate an understanding and use of the invention by those skilled in the art. It will be readily apparent to those skilled in the art that various modifications to these embodiments may be made, and the generic principles described herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above embodiments, and those skilled in the art should make improvements and modifications within the scope of the present invention based on the disclosure of the present invention.

Claims (8)

1. The pharmaceutical composition for reducing the postpartum inflammation of the sow is characterized by comprising the following components in parts by weight: 7-13 parts of antipyretic and antitoxic powder, 0.8-1.2 parts of compound amoxicillin powder, 4.2-5.7 parts of compound vitamin, 13-17 parts of glucose and 4.2-5.7 parts of astragalus polysaccharide powder.
2. The pharmaceutical composition for reducing postpartum inflammation of sows as claimed in claim 1, wherein the pharmaceutical composition comprises the following components in parts by weight: 8-12 parts of antipyretic and antitoxic powder, 0.9-1.1 parts of compound amoxicillin powder, 4.5-5.5 parts of compound vitamin, 14-16 parts of glucose and 4.5-5.5 parts of astragalus polysaccharide powder.
3. The pharmaceutical composition for reducing postpartum inflammation of sows as claimed in claim 1, wherein the pharmaceutical composition comprises the following components in parts by weight: 10 parts of antipyretic and antitoxic powder, 1 part of compound amoxicillin powder, 5 parts of compound vitamin, 15 parts of glucose and 5 parts of astragalus polysaccharide powder.
4. The pharmaceutical composition for reducing postpartum inflammation of sows according to claim 1, wherein the antipyretic and antitoxic powder comprises the following components in parts by weight: 1.2 parts of gypsum, 0.3 part of radix rehmanniae, 0.6 part of buffalo horn, 0.2 part of coptis, 0.3 part of gardenia, 0.2 part of tree peony bark, 0.25 part of scutellaria, 0.25 part of red peony root, 0.25 part of figwort, 0.3 part of rhizoma anemarrhenae, 0.3 part of weeping forsythia, 0.25 part of platycodon root, 0.15 part of liquorice and 0.25 part of lophatherum gracile.
5. The pharmaceutical composition for reducing postpartum inflammation of sows as claimed in claim 1, wherein said compound amoxicillin powder contains 0.5-1.5 wt% of amoxicillin and 0.2-0.3 wt% of clavulanic acid.
6. The pharmaceutical composition for reducing postpartum inflammation of sows as claimed in claim 1, wherein each 1kg of the vitamin complex comprises the following components: 1500-3000KIU vitamin A and 200-1000KIU vitamin D31000mg vitamin E500-11500 + 2000mg vitamin B2500-600mg vitamin B65-7mg vitamin B127000mg nicotinamide 5000-.
7. The pharmaceutical composition for reducing postpartum inflammation of sows as claimed in claim 6, wherein each 1kg of the vitamin complex comprises the following components: 2000KIU vitamin A, 600KIU vitamin D3700mg vitamin E, 1300mg vitamin K, 2200mg vitamin C, 1800mg vitamin B11800mg vitamin B2550mg of vitamin B66mg of vitamin B126000mg of nicotinamide, 6000mg of pantothenic acid, 370mg of folic acid and 60mg of biotin.
8. A process for the preparation of a pharmaceutical composition as claimed in any one of claims 1 to 7 for reducing postpartum inflammation in sows, the process comprising: the antipyretic and antitoxic powder, the compound amoxicillin powder, the compound vitamins, the glucose and the astragalus polysaccharide powder are uniformly mixed to obtain the pharmaceutical composition.
CN201911404120.7A 2019-12-30 2019-12-30 Pharmaceutical composition for reducing postpartum inflammation of sow and preparation method thereof Withdrawn CN111053852A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911404120.7A CN111053852A (en) 2019-12-30 2019-12-30 Pharmaceutical composition for reducing postpartum inflammation of sow and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911404120.7A CN111053852A (en) 2019-12-30 2019-12-30 Pharmaceutical composition for reducing postpartum inflammation of sow and preparation method thereof

Publications (1)

Publication Number Publication Date
CN111053852A true CN111053852A (en) 2020-04-24

Family

ID=70305114

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911404120.7A Withdrawn CN111053852A (en) 2019-12-30 2019-12-30 Pharmaceutical composition for reducing postpartum inflammation of sow and preparation method thereof

Country Status (1)

Country Link
CN (1) CN111053852A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112704159A (en) * 2020-11-18 2021-04-27 福建傲农生物科技集团股份有限公司 Feed premix for reducing inflammation after delivery of sows and preparation and application thereof
CN115192607A (en) * 2022-05-18 2022-10-18 陶圣颖 Antibacterial agent, preparation method and application thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112704159A (en) * 2020-11-18 2021-04-27 福建傲农生物科技集团股份有限公司 Feed premix for reducing inflammation after delivery of sows and preparation and application thereof
CN115192607A (en) * 2022-05-18 2022-10-18 陶圣颖 Antibacterial agent, preparation method and application thereof

Similar Documents

Publication Publication Date Title
CN108079284B (en) Medicine for improving sow production performance and preparation method and application thereof
CN111053852A (en) Pharmaceutical composition for reducing postpartum inflammation of sow and preparation method thereof
CN102727751A (en) Swine mineral powder for external use and preparation method thereof
CN1559470A (en) Chinese patent drug for livestock
CN104381633A (en) Lactogenic Chinese medicinal compound sow feed
CN103860633B (en) Plant composition for preventing cow mastitis
CN105168807A (en) Traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome and preparation method thereof
US4120952A (en) Method for the treatment of diarrhea in monogastric animals
CN106074839B (en) Veterinary drug composition for improving animal reproductive performance and preparation method thereof
CN103721008A (en) Traditional Chinese medicine veterinary drug for treating out of heat of livestock and preparation method of traditional Chinese medicine veterinary drug
CN101612392A (en) A kind ofly be used to prevent and treat preparation of mammalian endometritis and preparation method thereof
CN103720993A (en) Traditional Chinese medicine composition for improving dam ovulation quality
CN104322981A (en) Traditional Chinese medicine compound sow feed capable of promoting oestrus of weaning sows
AU2021103633A4 (en) a feed additive capable for improving breeding capability of Min breeding pigs and preparation method thereof
CN108653412A (en) A kind of Chinese medicine and the preparation method and application thereof for treating rush down dysentery
CN105396065A (en) Traditional Chinese medicine composition for treating long labor stage of sow
CN116077566B (en) Chinese herbal medicine composition for promoting oestrus of cows and preparation method thereof
CN103006889B (en) Traditional Chinese medicine preparation for promoting lactation of female livestock and preparation method and using method thereof
CN108653498B (en) Spleen-tonifying and growth-promoting pharmaceutical composition and application thereof
CN106309549A (en) Ultramicro-pulverised powder Chinese veterinary drug combination for promoting sow postpartum recovery and preparing method thereof
CN113058030B (en) Composition for preventing and treating flaccidity syndrome and application thereof
CN102379945B (en) Veterinary compound Chinese-western drug composition for defervescing and diminishing inflammation
CN105535097A (en) Cow anestrus treating composition containing traditional Chinese medicines
CN114848802A (en) Bioactive composition for preventing and/or treating retained afterbirth of dairy cow, application thereof, powder and tablet
CN106822866A (en) Sow is prevented miscarriage traditional Chinese powder medicine and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20200424

WW01 Invention patent application withdrawn after publication